CYAD News and Press, Celyad SA From 12/03/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Celyad Oncology (NASDAQ: CYAD ) stock is heading higher on Friday thanks to some recent news. Source: Kevin McGovern / Shutterstock.com The big announcement sending CYAD stock higher today is a $32.5 million ...

Gainers: Celyad Oncology CYAD +41%, Longeveron LGVN +28%, Petros Pharmaceuticals (NASDAQ:PTPI) +26%, AirSculpt Technologies AIRS +12%, Werewolf Therapeutics (NASDAQ:HOWL) +12%. Losers: Esperion Therapeutics ESPR -40%, Biofrontera (NASDAQ:...

Celyad Oncology (NASDAQ:CYAD) +31% raises $32.5M in private placement with Fortress Investment Group. Longeveron (NASDAQ:LGVN) +26% on FDA orphan designation to Lomecel-B Marvell Technology (NASDAQ:MRVL) +22% after third-quarter earnings beat Code Chain New Continent ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re at the end of the week and it starts off with the biggest pre-market stock movers for Friday! Source: Shutterstock Moving shares this morning are merger updates, earnings reports...

Celyad Oncology (NASDAQ:CYAD) has entered into a subscription agreement with an affiliate of Fortress Investment Group for the private placement of 6.5M ordinary shares for gross proceeds of $32.5M (about €28.7M). The Company will issue ordinary shares at $5.00/share (€4.42). Ne...

MONT-SAINT-GUIBERT, Belgium, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“Celyad” or the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T...

Preclinical data support armoring NKG2D CAR T cells with IL-18 to drive improved anti-tumor activity of the product candidate Development continues for second-generation multiplexing shRNA scaffold for novel non-gene edited CAR T candidates with desired phenotypes KE...

Celyad Oncology (NASDAQ:CYAD): 9M GAAP EPS of €1.49. Cash and cash equivalents of €6.1M. Press Release 6-K For further details see: Celyad Oncology reports 9M results

Phase 1b KEYNOTE-B79 trial set to evaluate CYAD-101 followed by KEYTRUDA ® in metastatic colorectal cancer (mCRC) patients with microsatellite stable disease on track to begin by year-end 2021 Enrollment continues at the highest dose level in Phase 1 IMMUNICY-1 tria...

MONT-SAINT-GUIBERT, Belgium, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that two abstrac...